Abstract: The subject invention relates to compositions in dosage form comprising a solid dispersion which is a solidified melt mixture consisting essentially of the following components:(a) from about 15% to about 75% of tebufelone;(b) from about 25% to about 65% of a poloxamer surfactant having a melting point of about 40.degree. C. or greater, the poloxamer surfactant consisting essentially of a block copolymer having three polymer blocks, a middle block of poly(oxypropylene) with a molecular weight of from about 1450 daltons to about 6000 daltons, and end blocks of poly(oxyethylene), the end blocks being from about 50% to about 90% of the copolymer; and(c) from 0% to about 60% of other components, wherein the other components are miscible with a melt mixture of components (a) and (b).
Abstract: The subject invention involves compositions comprising 4-(3,5-bis(1,1-dimethylethyl-4-hydroxyphenyl)-4-oxobutanamide, or 4-(3,5-bis-(1,1-dimethylethyl)-4-hydroxyphenyl)-4-oxobutanoic acid and pharmaceutically-acceptable salts thereof, and a pharmaceutically-acceptable carrier. The subject invention also involves methods for treating diseases characterized by inflammation and/or pain, such as rheumatoid arthritis and osteoarthritis, in humans or lower animals by administration of a safe and effective amount of this compound to the human or lower animal in need of such treatment.
Type:
Grant
Filed:
October 1, 1992
Date of Patent:
January 18, 1994
Assignee:
The Procter & Gamble Company
Inventors:
Roy L. M. Dobson, Kenneth R. Wehmeyer, Steven P. Sirko, Benjamin F. Floyd
Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a mutated p53 gene incapable of expressing p53 protein, b) a normal RB-1 gene, c) a 10-fold amplified c-myc gene, d) a normal c-fos gene, e) a deregulated immediate early gene response, f) a canalicular network MATRIGEL.TM. growth pattern, g) tumorigenic in congenitally athymic mice, h) no alkaline phosphatase activity, i) an ability to produce one or more growth factors selected from the group consisting of: 1) an osteoblastic differentiation growth factor, 2) a non-heparin binding mitogenic growth factor, 3) a first heparin binding mitogenic growth factor, 4) a second heparin binding mitogenic growth factor, and 5) a third heparin binding mitogenic growth factor, and j) an ability to be serially propagated greater than sixty population doublings.
Type:
Grant
Filed:
June 24, 1992
Date of Patent:
November 23, 1993
Assignee:
The Procter & Gamble Company
Inventors:
Claus-Jens W. Doersen, Robert J. Isfort
Abstract: The present invention relates to a composition for regulating hair growth comprising a safe and effective amount of the tripeptide histidyl-glycyl-glycine, or a derivative thereof, and a pharmaceutically-acceptable carrier.
Type:
Grant
Filed:
August 20, 1991
Date of Patent:
October 12, 1993
Assignee:
The Procter & Gamble Company
Inventors:
Kurt G. Kronholm, Richard J. Schwen, Mark R. Sine, Raphael Warren, Cynthia J. Wawrzyniak
Abstract: The present invention relates to novel chromophore-containing compounds useful as sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. These compounds comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are directly coupled to thereby form a new chromophore.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.
Abstract: The present invention relates to novel sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. The sunscreen agents comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are not directly coupled.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.
Type:
Grant
Filed:
August 5, 1992
Date of Patent:
July 27, 1993
Assignee:
The Procter & Gamble Company
Inventors:
Anthony D. Sabatelli, Josephine A. Spirnak
Abstract: The present invention relates to novel sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. The sunscreen agents comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are not directly coupled.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.
Type:
Grant
Filed:
August 5, 1992
Date of Patent:
July 20, 1993
Assignee:
The Procter & Gamble Company
Inventors:
Anthony D. Sabatelli, Josephine A. Spirnak
Abstract: The present invention relates to novel sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. The sunscreen agents comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are not directly coupled.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.
Type:
Grant
Filed:
August 5, 1992
Date of Patent:
July 20, 1993
Assignee:
The Procter & Gamble Company
Inventors:
Anthony D. Sabatelli, Josephine A. Spirnak
Abstract: The present invention relates to novel chromophore-containing compounds useful as sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. These compounds comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are directly coupled to thereby form a new chromophore.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.
Abstract: The present invention relates to novel sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. The sunscreen agents comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are not directly coupled.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans of lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.
Type:
Grant
Filed:
January 7, 1991
Date of Patent:
November 3, 1992
Assignee:
The Procter & Gamble Company
Inventors:
Anthony D. Sabatelli, Josephine A. Spirnak
Abstract: The present invention relates to novel chromophore-containing compounds useful as sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. These compounds comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are directly coupled to thereby form a new chromophore.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.
Abstract: The subject invention relates to methods for providing mucosal-protection comprising administering to a human or lower animal a safe and effective amount of an extract from plant species of the genera Wedelia, Eclipta and Aspilia.
Type:
Grant
Filed:
September 28, 1990
Date of Patent:
July 14, 1992
Assignee:
The Procter & Gamble Company
Inventors:
Tuticorin G. Rajagopalan, Jared L. Randall
Abstract: The subject invention relates to a process for the preparation of 2-alkyl-4-acyl-6-tert-butylphenol compound having the chemical structure: ##STR1## wherein -R is an aliphatic group having a terminally unsaturated moiety selected from --C.tbd.CH and --CH.dbd.C.dbd.CH.sub.2, and R' is selected from saturated, straight, branched or cyclic alkyl having from 1 to about 10 carbon atoms; the 2-alkyl-4-acyl-6-tert-butylphenol compound being produced in a reaction mixture comprising the corresponding 2-alkyl-6-tert-butylphenol: ##STR2## the corresponding carboxylic acid: RCOOH, and trifluoroacetic anhydride.
Abstract: The subject invention involves compositions and methods of using loperamide and related compounds for treatment of symptoms associated with respiratory diseases.
Type:
Grant
Filed:
January 25, 1991
Date of Patent:
May 26, 1992
Assignee:
The Procter & Gamble Company
Inventors:
Sheri A. Gilbert, Haruko Mizoguchi, Robert P. Charest, Timothy P. O'Neill, Ronald L. Smith
Abstract: The subject invention involves pharmaceutical compositions comprising a sulfated glyceroglucolipid having the structure: ##STR1## wherein n is an integer of from 1 to about 5, R is hydrogen or C.sub.1 -C.sub.24 acyl or alkyl, R' is hydrogen or C.sub.1 -C.sub.24 acyl or alkyl, and M.sup.+ is a cationic moiety, and methods of treating or preventing gastroduodenal diseases or disorders caused by or associated with H. pylori by administering such compounds.
Abstract: This invention relates to a method for treating or preventing anaerobe infections in humans and lower animals. This invention further relates to compositions and kits containing peroxy acids useful for treating or preventing anaerobe infections according to the method of the present invention.
Abstract: The present invention relates to beta-aminoethyl-substituted phenyl compounds, especially beta-aminoethoxy-substituted phenyl compounds. The present invention also relates to pharmaceutical compositions comprising a safe and effective amount of a compound of the present invention and a pharmaceutically-acceptable carrier. The present invention further relates to methods for producing analgesia and reducing inflammation, in humans and lower animals, by administering the compounds or compositions of the present invention. In addition, the present invention relates to methods for making compounds of the present invention and intermediates useful in these synthesis methods.
Type:
Grant
Filed:
June 27, 1991
Date of Patent:
March 24, 1992
Assignee:
The Procter & Gamble Company
Inventors:
Joseph H. Gardner, Gerald B. Kasting, Thomas L. Cupps, Richard S. Echler, Thomas W. Gibson, Joel I. Shulman
Abstract: The subject invention involves halogenated amino acid derivatives useful as antimicrobial agents having the structure: ##STR1## wherein --R is hydrogen or 2-aminoethyl; --R' is hydroxy, alkoxy, aryloxy, or an amino acid residue bonded at the amino nitrogen; --R" is hydrogen or an amino acid residue bonded at the carbonyl carbon; --X is halogen; and --Y is hydrogen or halogen.
Abstract: A composition suitable for topical application to mammalian skin or hair comprising an amount of a cell-free supernatant from a culture of dermal papilla cells sufficient to increase hair growth in mammals.
Type:
Grant
Filed:
May 22, 1990
Date of Patent:
February 25, 1992
Assignee:
The University of Dundee
Inventors:
Travis E. J. Buultjens, Stephen W. Hellens, Colin A. B. Jahoda, Roy F. Oliver, Anne P. Withers
Abstract: Disclosed is a composition for regulating hair growth comprising a safe and effective amount of a polypeptide having the structure of those derived from dermal papilla cells with characteristics of apparent isoelectric pH/molecular weight selected from the group consisting of pI 5.1/45kD, pI 5.2/43kD, pI 5.2/40kD, pI 7.3/25kD, pI 7.4/25kD, or active fragment of these polypeptides, and mixtures thereof; and a pharmaceutically-acceptable carrier.
Type:
Grant
Filed:
April 12, 1990
Date of Patent:
November 26, 1991
Assignee:
University of Dundee
Inventors:
Travis E. J. Buultjens, Colin A. B. Jahoda, Roy F. Oliver